Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Director Buys $1,673,242.80 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Director Ra Capital Management, L.P. bought 68,018 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were purchased at an average cost of $24.60 per share, with a total value of $1,673,242.80. Following the purchase, the director directly owned 6,314,525 shares of the company’s stock, valued at $155,337,315. The trade was a 1.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Price Performance

Shares of COAG stock traded up $0.01 during mid-day trading on Wednesday, hitting $25.01. The company’s stock had a trading volume of 569,606 shares, compared to its average volume of 536,569. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.48 and a 52 week high of $36.61.